GSTM1 and chronic kidney disease: The results of CHOIR and CREATE prompted the FDA, in 2007, to direct manufacturers of ESA products in the United States to add a “black box” warning recommending the maintenance of Hb levels within the range of 10–12 g/dL for anemic patients with CKD (US Food and Drug Administration, 2007b).